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ABSTRACT
Dendritic cells have been used effectively to select for human cytomegalovirus (CMV)–specific T cells for
immunotherapy applications. The ability to process and present relevant major histocompatibility complex
class I and II peptides to T cells makes them ideal for selecting CD4 and CD8 T cells regardless of HLA
tissue type. This study compared the generation of CMV-specific T cells by using dendritic cells loaded
with either CMV pp65(495-503) peptide or CMV lysate or transduced with adenovirus encoding the pp65
gene (Ad5pp65GFP) for the generation of CD4 and CD8 CMV-specific T cells in HLA-A2 and
HLA-A2 donors. In HLA-A2 donors, CD8 tetramer T cells increased with all antigens but were
greatest in peptide- and Ad5pp65GFP-stimulated T cells. The CD4/CD8 ratio in the stimulated T-cell
cultures proved to be dependent on the antigen used. CMV lysate–stimulated cells were primarily CD4,
whereas peptide- and Ad5pp65GFP-stimulated cultures were mostly CD8. Analysis of cells from lysate-
stimulated or gene-transduced–stimulated cultures showed expansion of CMV-specific CD4 T cells,
indicating that major histocompatibility complex class II peptides were present in both antigens. Further-
more, CMV-specific T cells were generated from HLA-A2 donors by using Ad5pp65GFP transduction or
CMV lysate stimulation and were able to recognize a pp65 peptide restricted to the HLA-B35 allele. These
data indicate that either CMV lysate or adenovirus encoding CMV antigenic genes may be useful for the
generation of both CD4 and CD8 CMV-specific T cells in donors irrespective of HLA tissue type and
may be applicable to clinical immunotherapy.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Human ● CTL ● Viral ● Antigens ● Peptides ● Epitopes ● Transplantation
p
i
c
c
(
w
tNTRODUCTION
Initial studies [1,2] established the feasibility of
estoring immunity toward cytomegalovirus (CMV)
ith CMV-speciﬁc T-cell clones in immune-sup-
ressed patients undergoing allogeneic hematopoi-
tic stem cell transplantation. Although this novel
pproach provides proof of principle of the clinical
eneﬁts of T-cell adoptive immunotherapy, several
B&MTractical limitations of this treatment strategy were
dentiﬁed, including (1) difﬁculty in isolating T-cell
lones, (2) selection of T-cell clones excluding T
ells speciﬁc for other CMV antigenic proteins, and
3) lack of CMV-speciﬁc CD4 T-helper cells,
hich may be important in the efﬁcacy and persis-
ence of transferred effector cells [2-5].To shorten the complexity and time of the in vitro
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7election process, several investigators have used den-
ritic cells (DCs) pulsed with major histocompatibility
omplex (MHC) class I HLA-restricted peptides de-
ived from the immunodominant CMV structural
rotein pp65 [6-9]. Data from these studies show that
eptide-speciﬁc T cells can be selected in a relatively
hort time (4 weeks) and that these cells are function-
lly active against CMV. However, this approach has
everal shortcomings. First, it does not address the
mportance of CD4 T cells in the efﬁcacy of trans-
erred T cells. Second, it is not applicable across all
atient HLA haplotypes (eg, HLA-B7 or HLA-B35).
inally, stimulation with a peptide against a single
-cell epitope ignores the importance of a diverse,
athogen-speciﬁc immune response.
Ideally, stimulatory antigens would consist of
pitopes for CD4 T-cell recognition, as well as
D8 T cells. Options for this purpose would include
hole virus lysate (derived from CMV-infected cells)
r the transfection of genes that encode immunodom-
nant CMV proteins, such as pp65 [10]. These have
een shown to produce T-cell cultures capable of a
road antigen response, in contrast with CMV peptide
pitopes, which result in a narrow immune response
3,11,12]. Furthermore, the use of broad-repertoire
ntigens removes the need for a priori knowledge of
he HLA tissue type. Therefore, a system for gener-
ting CMV-speciﬁc T cells that includes CMV-spe-
iﬁc CD4 and CD8 T cells against a broad range of
MV epitopes may increase the efﬁcacy of adoptively
ransferred T cells. In this study, we investigated the
otential of CMV lysate and adenovirus encoding
MV pp65 for generating a broad CMV-speciﬁc T-
ell response in both HLA-A2 and HLA-A2 do-
ors.
ATERIALS AND METHODS
onor Population
Peripheral blood was collected from healthy
MV-seropositive individuals. Peripheral blood
ononuclear cells (PBMCs) were isolated by standard
icoll gradient centrifugation. CMV serology was as-
essed with enzyme-linked immunoabsorbent assay
or immunoglobulin M and immunoglobulin G anti-
odies for CMV late antigens [13]. HLA-A2 status
as determined by serologic typing or by staining
ith the HLA-A2 monoclonal antibody CR11.351
14].
eneration of CMV Antigen–Loaded DCs
Monocyte-derived DCs were generated as previ-
usly described [15]. Brieﬂy, monocytes were en-
iched by plastic adherence and cultured for 5 days in
PMI supplemented with 1% pooled AB serum and
000 U/mL granulocyte-macrophage colony-stimu- f
62ating factor and interleukin (IL)–4 (Chemicon, Te-
ecula, CA). Immature DCs were incubated with 75
L of CMV lysate (BioWhittaker, Walkersville, MD)
r transduced with adenoviral vector encoding the
atrix protein CMV pp65 and green ﬂuorescence
rotein (GFP; constructed and supplied by Dr. C
ooney and colleagues, Center for Cell and Gene
herapy, Houston, TX) at a multiplicity of infection
f 500 plaque-forming units per cell. DCs were ma-
ured for 2 days by the addition of tumor necrosis
actor- 200 U/mL (Chemicon). For peptide pulsing,
ature DCs were incubated with the 9-mer peptide
MV pp65(495-503) (NLVPMVATV, termed NLV;
imotopes, Clayton, VIC, Australia) at a concentra-
ion of 10 g/mL for 2 hours. In some assays, control
ysate (BioWhittaker) or adenoviral vector encoding
FP alone (provided by Dr. A. Davis, Center for Cell
nd Gene Therapy, Houston, TX) was used as a neg-
tive control.
utologous Mixed Lymphocyte Reaction with
MV-Loaded DCs
Mixed lymphocyte proliferation assays were per-
ormed to evaluate whether the described CMV anti-
ens were capable of eliciting an immune response in
itro. A total of 103 DCs were incubated with NLV
eptide, CMV lysate, or Ad5pp65GFP; irradiated (30
y); and cocultured with 104 autologous PBMCs for 5
ays in quadruplicate in microtiter plates. The cells
ere harvested on day 6 after an 18-hour incubation
eriod in the presence of [3H]thymidine. Proliferation
as then measured on a MicroScint counter (Packard,
eriden, CT).
eneration of CMV-Specific T Cells
CMV-speciﬁc T-cell cultures were generated by
sing a previously described method [15]. Brieﬂy,
MV antigen–loaded DCs were irradiated (30 Gy)
nd cocultured with 2  106 autologous PBMCs at a
atio of 1:10 DCs to PBMCs in AIM V (Gibco, Grand
sland, NY) with 10% heat-inactivated pooled human
B serum in 24-well plates (Costar, Cambridge, MA).
n day 7, cultures were restimulated with antigen-
oaded DCs as described previously, and medium was
upplemented with 20 U/mL IL-2 (Chemicon). Me-
ium was changed every 2 to 3 days with half fresh
edia and IL-2. On day 14, T-cell cultures were
arvested and resuspended at 5  105/mL in fresh
edia containing 50 U/mL IL-2 and expanded in
L-2–containing media in the absence of further stim-
lation.
mmunophenotyping
Transduction efﬁciency of Ad5pp65GFP into DC
ultures was determined by ﬂow cytometry analysis
or cells that were dually positive for GFP and staining
w
B
w
w
(
C
o
s
H
t
M
t
j
5
2
w
p
(
F
C
d
(
T
s
e
t
H
(
s
p
[
H
i
t
p
l
b
t
5
w
%
m

I
A
a
(
u
C
s
C
l
l
p
w
c
g
n
a
a
t
w
t
c
R
P
h
H
a
T
f
T
a
s
t
P
v
g
d
w
c
m
G
P
C
c
A
T
N
*
CMV Antigens for Immunotherapy
Bith monoclonal antibody CD11c phycoerythrin (PE;
ecton Dickinson, San Jose, CA) after gating on cells
ith high forward- and side-scatter properties. T cells
ere analyzed by PE- or ﬂuorescein isothiocyanate
FITC)–conjugated antibodies against CD3, CD4,
D8, and CD56 (Becton Dickinson). The speciﬁcity
f CMV-speciﬁc T cells toward NLV in HLA-A2
amples was determined by soluble MHC peptide
LA-A*0201–restricted NLV tetramers conjugated
o PE (Beckman Coulter, Immunomics Division,
arseille, France). Characterization of T-cell recep-
or (TCR) V usage was performed with FITC-con-
ugated V antibodies directed against V 1, 2, 3, 5.1,
.2, 5.3, 7, 8, 9, 11, 12.2, 13.1, 13.6, 14, 16, 17, 18, 20,
1.3, 22, and 23 (Beckman Coulter, Fullerton, CA),
ith the addition of anti-CD3 peridinin-chlorophyll-
rotein complex (PerCP) and anti-CD4 or -CD8 PE
Becton Dickinson). All samples were analyzed on a
ACSCalibur ﬂow cytometer (Becton Dickinson).
ytotoxicity Assays
Cytotoxicity assays were performed with a stan-
ard 4-hour chromium 51 release against T2 cells
CEM.T2 hybridoma, HLA-A2, and TAP1 and
AP2 deﬁcient) or autologous DCs. To evaluate the
peciﬁcity against different known CMV T-cell
pitopes, several peptides were synthesized (Mimo-
opes), including NLVPMVATV (CMV pp65(495-503),
LA-A2 restricted; termed NLV), VLEETSVML
CMV immediate-early 1 [IE1](316-324), HLA-A2 re-
tricted, termed VLE), VFPTKDVAL (CMV
p65(187-195), HLA-B35 restricted, termed VFP)
16,17], and VLQELNVTV (PR1 control peptide,
LA-A2 restricted, termed VLQ). All peptides were
ncubated with mature DCs or T2 cells at a concen-
ration of 10 g/mL for 2 hours. Cytotoxicity was also
erformed against autologous DCs loaded with CMV
ysate, transduced with Ad5pp65GFP, or mock-loaded
y using the protocol described previously. Cells were
hen washed and incubated with 100 Ci of chromium
1 per 106 target cells for 90 minutes. Speciﬁc lysis
as calculated as follows:
lysis  experimental release 
inimum release
maximum release  minimum release100
nterferon- Enzyme-Linked Immunosorbent
ssay
To assess the presence of CMV-speciﬁc CD4
nd CD8 T cells in culture, a standard interferon
IFN)– enzyme-linked immunosorbent assay was
sed. First, cultures were labeled with CD4 FITC and
D8 PE antibodies and sorted by ﬂuorescence inten-
ity on a FACSVantage (Becton Dickinson) cell sorter.
D4 and CD8 cells were then cocultured in trip-icate in microtiter plates with DCs pulsed with CMV t
B&MTysate, Ad5pp65GFP-transduced DCs, or mock-
ulsed DCs. After overnight culture, the supernatant
as harvested and transferred to immunoassay plates
oated with anti-human IFN- antibody (Pharmin-
en, San Diego, CA). The plates were incubated over-
ight at 4°C, washed, and incubated with biotinylated
nti–IFN- antibody (Pharmingen). After incubation
nd subsequent washing, the plate was developed by
he addition of streptavidin peroxidase, and the wells
ere quantiﬁed by light absorbance. The experimen-
al values were then compared with an IFN- standard
urve (range, 25-3000 pg/mL).
ESULTS
atient Samples
PBMCs were isolated from CMV-seropositive
ealthy donors who were either HLA-A2 (n  5) or
LA-A2 (n  3). All HLA-A2 donors were char-
cterized for complete tissue typing (Table 1).
ransduction of DCs with Ad5pp65GFP
Introduction of Ad5pp65GFP into DCs was per-
ormed during the immature phase of DC generation.
he addition of tumor necrosis factor- on day 5
llowed time for the expression, processing, and pre-
entation of pp65 peptides along with the upregula-
ion of costimulatory molecules before coculture with
BMCs. The inclusion of the GFP gene in the Ad5
ector allowed determination of the efﬁciency of pp65
ene transfer. From 3 separate donors, a mean trans-
uction efﬁciency of 60%	26% (range, 29%-75%)
as achieved by measuring production of GFP by ﬂow
ytometry after 7 days of culture. In comparison,
ock-infected DCs showed a complete absence of
FP expression (Figure 1).
roliferation in Response to Ad5pp65GFP and
MV Lysate
To demonstrate that CMV antigen can be pro-
essed and presented after transduction with
d5pp65GFP, autologous [3H]thymidine prolifera-
able 1. Tissue Typing of Donors
Donor No. HLA-A HLA-B HLA-DRB1
1 2, 24 8, 1402 0101, 03
2 2* ND ND
3 2* ND ND
4 2* ND ND
5 2, 26 35, 41 11, 15
6 1, 26 35 11, 13
7 1, 3 37, 41 07
8 26, 31 7, 35 09012, 15011
D indicates not determined.
HLA-A2 was determined by CR11.351 antibody.ion assays were performed. Ad5pp65GFP-transduced
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7Cs were able to efﬁciently produce immunogenic
eptides derived from CMV pp65. DCs transduced
ith Ad5pp65GFP induced signiﬁcantly more prolif-
ration of autologous PBMCs than did DCs trans-
uced with Ad5GFP alone (Figure 2A). In a healthy
onor analyzed for proliferation, GFP did not seem to
ontribute to T-cell proliferation, indicating that
MV-derived antigens dominated the immune re-
ponse. Similarly, an increase in proliferation was ob-
erved when PBMCs were cocultured with DCs
oaded with CMV lysate, but not with control lysate
Figure 2B). It can be assumed that under these con-
itions, CMV lysates (eg, CMV peptides and proteins)
ere processed and presented appropriately for T-cell
ecognition.
eneration of CMV-Specific CD4 and CD8 T
ells from HLA-A2 Donors
Three different antigen preparations were ana-
yzed for the generation of CMV-speciﬁc T cells by
sing our previously described method [15]. We eval-
ated the phenotype and function of PBMCs stimu-
ated with NLV peptide, CMV lysate, and
d5pp65GFP by generating CMV-speciﬁc T cells
rom 5 healthy HLA-A2 donors. Examination of the
igure 1. Transduction of DCs with Ad5pp65GFP. DCs were
ncubated on day 5 with Ad5pp65GFP and analyzed on day 7 for the
xpression of GFP. DCs were gated by high forward and side scatter
A) and analyzed by comparing CD11c and GFP expression on
ontransduced DCs (B) and Ad5pp65GFP-transduced DCs (C).ulture phenotype showed that NLV-stimulated cul- c
64ures were dominated by CD8 T cells, in which a
ean of 78%	12% (range, 66%-95%) were CD8
nd only 12%	6% (range, 5%-19%) were CD4
Table 2). This contrasted with T-cell cultures stim-
lated with CMV lysate, in which a complete reversal
f the CD4/CD8 ratio was observed. CD4 T cells
omprised 70%	12% (range, 55%-75%) of the lym-
hoid population, whereas the frequency of CD8 T
ells was 14%	8% (range, 9%-25%). Ad5pp65GFP
roduced an intermediate phenotype, with CD8
aking up 62%	21% (range, 46%-82%) and CD4
omprising 29%	10% (range, 17%-36%). All cell
ultures showed 
10% CD56 cells and were nega-
ive for CD19 lymphocytes (
1%; Table 2).
xpansion of NLV-Specific T Cells from HLA-A2
onors
CMV-speciﬁc T-cell cultures from 3 HLA-A2 do-
ors (donors 1, 2, and 5) were examined for the expan-
ion of NLV-speciﬁc CD8 T cells by ﬂow cytometry
ith NLV tetramer. All cultures, regardless of antigen
ype, showed expansion of tetramer CD8 T cells.
owever, the frequency of tetramer cells varied be-
ween cultures stimulated by antigens derived only from
he pp65 protein (NLV peptide or Ad5pp65GFP) and
ultures subjected to stimulation by a broad range of
ntigens found in CMV lysate (Figure 3). NLV-stimu-
ated cultures were primarily CD8 tetramer, with a
ean frequency of 61%	19% (range, 55%-95%) after
1 days in culture. Likewise, Ad5pp65GFP-transduced
Cs induced strong stimulation of T cells that recog-
ized the NLV epitope. A large portion of the lympho-
ytes were tetramer (36%	27%; range, 25%-58%),
igure 2. Autologous mixed lymphocyte reaction with CMV-
oaded DCs. DCs were analyzed for the ability to stimulate CMV-
peciﬁc proliferation in a CMV-seropositive donor. (A) Prolifera-
ion of PBMCs stimulated with DCs that were mock-transduced, or
ransduced with Ad5GFP only or Ad5pp65GFP encoding pp65,
nd then used in a 5-day [3H]thymidine proliferation assay in
uadruplicate. (B) Proliferation of PBMCs stimulated with DCs
ncubated with CMV lysate was compared with DCs loaded with
ontrol antigen and mock-loaded DCs. PBMCs and DCs were also
ompared for proliferation alone. *P 
 .05 against DCs loaded with
ontrol antigen.
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CMV Antigens for Immunotherapy
Bnd this reﬂects the ability of DCs transduced with
d5pp65GFP to process and present NLV peptide on
HC class I molecules and the immunodominance of
his epitope in some HLA-A2 individuals (Table 2).
MV lysate–pulsed DCs, conversely, generated lower,
ut measurable, levels of tetramer CD8 T cells. In
hese cultures, 8%	6% (range, 1%-12%) of the T-cell
opulation recognized NLV by tetramer analysis. The
xpansion of NLV-speciﬁc T cells in CMV lysate–stim-
lated cultures peaked at day 14 and declined in fre-
uency as the culture progressed, presumably because of
ncreased CD4 T-cell numbers (data not shown). A
omparison of total cell number and the absolute num-
er of NLV-speciﬁc cytotoxic T lymphocytes (CTLs)
enerated under different antigen-stimulation condi-
ions indicated that NLV-pulsed DCs were superior at
xpanding both bulk cell numbers and NLV-speciﬁc
TLs (Figure 4; Table 2). NLV stimulation produced a
0	31-fold total cell number expansion, as compared
ith a 15	9-fold expansion with Ad5pp65GFP stimu-
ation and a 12	2-fold expansion with CMV lysate–
ulsed DCs after 21 days in culture. NLV-stimulated
ultures showed the greatest expansion of NLV-speciﬁc
TLs, with a 3929	196-fold tetramer cell expansion
igure 3. Tetramer expansion after stimulation with different
MV antigen types. The frequency of CD8 tetramer T cells was
ompared after PBMCs from a CMV-seropositive donor were stim-
lated with DCs loaded with NLV peptide, Ad5pp65GFP, or CMV
ysate. Unstimulated PBMCs are shown on the left, and CMV-
peciﬁc T-cell cultures are shown at day 7 and 14 for their respec-
able 2. Comparison of Phenotype and Expansion with Different CMV
Antigen
Mean Expressio
Tetramer
CD8 CD4 CD
LV 61  19 12  6 78
d5pp65GFP 36  27 29  10 62
MV lysate 8  6 70  12 14
Gated on lymphocytes as deﬁned by forward- and side-scatter proﬁle.
Calculated by multiplying the tetramer CD8 percentage against totcive antigen types.
B&MTompared with a 614	549-fold expansion in
d5pp65GFP cultures and a 55	74-fold expansion in
ultures stimulated with CMV lysate (Figure 4; Table 2).
Cells generated under these conditions were ca-
able of speciﬁcally killing T2 target cells when pulsed
ith NLV peptide but failed to recognize the control
eptide VLQ (derived from proteinase-3). The most
ell lysis was observed in NLV- and Ad5pp65GFP-
timulated T cells compared with CMV lysate–stimu-
ated T cells (Figure 5A). These data demonstrate
oncordance between the number of NLV-speciﬁc
ells by tetramer analysis and speciﬁc lysis of NLV-
ulsed target cells. Cell cultures were then analyzed
or their ability to recognize a non-pp65 T-cell
pitope, the HLA-A2–restricted peptide VLE, de-
ived from CMV IE1. In these analyses, only T cells
timulated with CMV lysate were able to speciﬁcally
ecognize the VLE epitope (Figure 5B). T-cell cul-
ures stimulated with NLV or transduced with
d5pp65GFP failed to respond.
eneration of CMV-Specific CD4 T Cells
Both DCs loaded with CMV lysate and those
ransduced with Ad5pp65GFP should have the capa-
ility to present MHC class II–restricted peptides to
D4 T cells. To investigate whether CMV-speciﬁc
D4 T cells were generated through CMV antigen–
oaded DC stimulation, we measured CD4 T cells
or TCR V expansion (because of a lack of available
MV/MHC class II tetramers) and production of
FN- by sorted CD4 T cells in response to CMV
ntigen. For TCR V analysis, we hypothesized that
mmunodominant CD4 epitopes would cause expan-
ion of CD4 clones and that these would be visual-
zed by TCR V antibody staining. To test this,
D4 gated T cells were analyzed for TCR V ex-
ression by ﬂow cytometry and compared with normal
BMCs (Figure 6). We observed expansion of similar
D4 TCR V regions in 2 cases (donors 1 and 2)
hen cells were stimulated with either Ad5pp65GFP
r CMV lysate. Donor 1 showed expansion of TCR
 9 and 20 in both Ad5pp65GFP-stimulated and
MV lysate–stimulated cultures, whereas donor 2
howed expansion of TCR V 16. These results indi-
ns on Day 21 of Culture
-Fold Expansion
CD19 CD56 Total Tetramer†
<1 3  6 40  31 3929  196
<1 8  7 15  9 614  549
<1 4  4 12  2 55  74
umber before and after stimulation.Antige
n (%)*
8
 12
 21
 8ate that in these 2 donors, CMV-speciﬁc CD4 T
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7ells recognize epitopes derived from the pp65 pro-
ein, which is present in both Ad5pp65GFP and CMV
ysate.
To verify that the Ad5pp65GFP-stimulated and
MV lysate–stimulated cultures contained CMV-spe-
iﬁc CD4 T cells as well as CMV-speciﬁc CD8 T
ells (as demonstrated by tetramer), the CD4 T cells
rom CTL cultures were isolated with a cell sorter
purity90%) and tested for the production of IFN-
n response to antigen stimulation. In both culture
onditions, CD4 T cells produced IFN- when
timulated with DCs transduced with Ad5pp65GFP
r loaded with CMV lysate, but they did not react to
ontrol DC stimulation (Figure 7). This indicates that
D4T cells are stimulated by MHC class II peptides
nd that these culture conditions generate functionally
ompetent CD4 and CD8 CMV-speciﬁc T cells.
eneration of CMV-Specific T Cells from
LA-A2 Donors
Both Ad5pp65 and CMV lysate provide a means
or stimulating either CD4 or CD8 CMV-speciﬁc
cells for adoptive immunotherapy, regardless of
onor HLA tissue type. Therefore, we examined the
ossibility of generating CMV-speciﬁc T cells by us-
ng Ad5pp65 and CMV lysate from HLA-A2, CMV-
eropositive donors (n  3; Table 3). Cultures stim-
lated by Ad5pp65GFP or CMV lysate–loaded DCs
isplayed a similar phenotype to HLA-A2 T-cell
ultures. CMV lysate cultures were primarily CD4
igure 4. Expansion of CMV-speciﬁc T cells from a single HLA-A2
etramer CD8 T cells (B) were enumerated after 21 days in cult
ith DCs loaded with Ad5pp65GFP (●), CMV lysate (), or NLV62%	12%), with moderate CD8 T-cell represen- f
66ation (26%	12%). Ad5pp65GFP-stimulated cul-
ures, however, showed a more even CD4/CD8
atio; CD4 made up 57%	23% of the population,
nd 35%	21% of the cells were CD8. The overall
ell number expansion in these donors after 21 days in
ulture was similar to that in HLA-A2 donors, with
d5pp65GFP stimulating a 10	5-fold expansion and
MV lysate generating a 15	7-fold expansion in
LA-A2 donor T-cell cultures.
Examination of cytotoxicity showed that
d5pp65GFP-stimulated CTLs were able to lyse
p65-transduced DC target cells but failed to recog-
ize mock-pulsed DCs (Figure 8A). Furthermore,
hese cells were able to efﬁciently lyse DCs pulsed
ith CMV lysate but did not recognize DCs pulsed
ith a control antigen. Likewise, CMV lysate–stimu-
ated CTLs produced the same effect observed in
LA-A2 donors. The cells derived from an HLA-
2 donor speciﬁcally recognized autologous DCs
ransduced with Ad5pp65GFP and DCs pulsed with
MV lysate, but they failed to kill control target cells
Figure 8B). Conversely, each of the T-cell cultures
as able to lyse DCs presenting either Ad5pp65GFP
r CMV lysate, thus showing the importance of pp65
n generating an immune response. We then exam-
ned whether other non–HLA-A2 peptides could be
resented to HLA-A2 donors through stimulation
ith Ad5pp65GFP and CMV lysate. We used the
eptide VFP, which is a HLA-B35–restricted peptide
erived from pp65 [16,17]. CTLs were generated
r after stimulation with CMV-loaded DCs. Total cells (A) and total
m HLA-A2 donors (n  3; donors 1, 2, and 5) after stimulation
e (‘). dono
ure frorom donor 6 (homozygous for HLA-B35) by stimu-
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Bation with Ad5pp65GFP and CMV lysate. As a con-
rol, DCs were also loaded with the VFP peptide
lone. Cytotoxicity was then performed against autol-
gous VFP-loaded DC targets (Figure 8C). Both
d5pp65GFP-stimulated and CMV lysate–stimulated
cells from this donor were able to recognize the
LA-B35–restricted pp65 peptide when compared
gainst control loaded targets, as were CTLs stimu-
ated with the peptide alone. This demonstrates that
oth Ad5pp65GFP and CMV lysate are capable of
enerating non–HLA-A2-restricted, CMV-speciﬁc
-cell responses.
ISCUSSION
Adoptive immunotherapy with CMV-speciﬁc T
igure 5. Cytotoxicity of CMV-speciﬁc T-cell cultures against
eptide-pulsed T2 target cells. (A) The cytotoxicity of CMV-spe-
iﬁc T-cell cultures generated by DCs loaded with NLV peptide
triangles), Ad5pp65GFP (squares), and CMV lysate (circles) was
ested against that of chromium-labeled T2 cells loaded with NLV
eptide (closed symbols) or the irrelevant peptide VLQ (open sym-
ols). (B) CMV-speciﬁc T-cell cultures stimulated with CMV lysate
●), Ad5pp65GFP (), or NLV peptide (‘) were tested against T2
ells loaded with the CMV IE1 peptide VLE.ells, in particular, has shown promise in restoring a
B&MTmmunity in patients who are immune suppressed
1,2]. To simplify the selection of CMV-speciﬁc T
ells, several groups have investigated the prospect of
sing peptides derived from CMV pp65 to select
D8 cytotoxic T cells for immunotherapeutic pur-
oses [6-8,18]. These methods of CMV-speciﬁc T-
ell enrichment are relatively quick and simple, but
he use of MHC- and HLA-restricted epitopes, such
s NLV, results in narrow T-cell speciﬁcity and limits
atient eligibility based on tissue type. Furthermore,
cells selected under this type of antigen stimulation
arely include CD4 T-helper cells speciﬁc for the
athogen. One approach to improve on these deﬁ-
iencies is to stimulate an immune response with DCs
oaded with CMV lysate or transduced with the full-
ength pp65 protein [3,11,12,19,20]. This process al-
ows DCs to present a variety of HLA-restricted
pitopes on MHC class I and II molecules, thus al-
owing the generation of both CD4 and CD8
MV-speciﬁc T cells. However, the nature of the in
itro response of T cells (ie, expansion, speciﬁcity, and
unction) has not been directly compared between
arious antigen types.
DCs are professional antigen-presenting cells that
ave the ability to take up foreign proteins, degrade
hese proteins into antigenic peptides, and then
resent them on their surface in association with
HC class I or II molecules [21-23]. Simulation with
d5pp65GFP and CMV lysate to generate CMV-
peciﬁc T cells relies on these DC properties. Trans-
uction of DCs with Ad5pp65GFP proved relatively
asy. Up to 70% of the DCs were shown to express
he GFP marker, indicating that proteins transferred
rom Ad5pp65GFP were being produced by the DCs.
Cs were able to produce pp65, which was then
rocessed into MHC class I– and II–restricted pep-
ides, as shown by the expansion of CD8 tetramer
nd CD4 TCR V–restricted T cells after stimula-
ion. Likewise, CMV lysate was able to produce sim-
lar effects in terms of T-cell expansion, indicating
hat proteins and peptides found in the cell lysate were
ffectively taken up and presented by DCs.
Comparison between NLV peptide–stimulated T
ells and PBMCs stimulated by Ad5pp65GFP and
MV lysate showed that it was possible to generate
MV-speciﬁc CD4 T cells within the last 2 cultures.
xperiments with CMV lysate as the antigen pro-
uced results similar to those previously published by
eggs et al. [11] and Einsele et al. [3]. In these cul-
ures, NLV tetramer expansion occurred, but overall
ell expansion was dominated by CD4 T cells. Cul-
ures were able to lyse NLV-pulsed target cells and
LE-pulsed target cells, indicating that the CMV IE1
rotein is also represented in the antigen preparation.
nalysis by TCR V antibodies showed expansion of
estricted CD4 TCR V regions; this may be indic-
tive of CMV-speciﬁc T-cell expansion. This was
767
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7onﬁrmed by sorting CD4 T cells and measuring
FN- production in response to CMV antigen stim-
lation. This indicates that MHC class II peptides (or
roteins that may be degraded into MHC II peptides)
re well represented in this antigen preparation and
hat it may be a useful tool for selecting CD4 T cells.
In agreement with data presented by Keever-Tay-
or et al. [12] and Carlsson et al. [19], Ad5pp65GFP-
timulated cultures produced CD8 T cells with a
igh frequency of NLV tetramer T cells, thus re-
ecting the dominance of the CD8 pp65 response in
LA-A2 CMV-seropositive individuals. However,
d5pp65GFP-stimulated cultures also contained
MV-speciﬁc CD4 T cells in numbers intermediate
etween those observed with NLV- and lysate-stim-
lated cultures. CD4 T cells showed expansion of
CR V regions similar to cultures stimulated with
MV lysate, thus demonstrating that the pp65 protein
ontains MHC class II–restricted epitopes, as well as
he immunodominant NLV MHC class I peptide.
ther investigators have also identiﬁed and isolated
igure 6. TCR V analysis of CD4 CMV-speciﬁc T cells. To
timulation, the CD4 TCR V frequency was analyzed on 2 do
timulation and after 2 stimulations with DCs loaded with either A
D4 TCR V regions between stimulating antigens.D4 CMV-speciﬁc T cells after Ad5pp65-trans- s
68uced DC stimulation [12] or by using a combination
f peptides and lysate for stimulation [24]. The latter
pproach combined peptide and lysate stimulation
ith large-scale culture, isolation of IFN-secreting
ells with a magnetic bead system, and culture in IL-2
ith irradiated autologous feeder cells. Expansion of
ells was rapid, but these procedures increase the cost
nd complexity of cell generation. Our data demon-
trate an equivalent expansion of CMV-speciﬁc (as
udged by expansion of tetramer cells) cells with a
ubstantially simpler culture method.
Finally, we investigated the potential for generat-
ng CMV-speciﬁc T cells from HLA-A2 donors
timulated with CMV lysate and Ad5pp65GFP.
d5pp65GFP-stimulated cultures showed a greater
ercentage of CD4 T cells, suggesting that CD4
pitopes within pp65 were common among the MHC
lass II antigens expressed by the HLA-A2 donors.
oth CMV lysate–stimulated and Ad5pp65GFP-stim-
lated cultures demonstrated the ability to lyse autol-
gous CMV antigen–loaded DCs in cytotoxicity as-
whether CD4 T cells expanded in response to CMV antigen
onor 1 and 2; panel 1 and 2, respectively) before CMV antigen
5GFP or CMV lysate. Hashed boxes indicate expansion of similarassess
nors (d
d5pp6ays but failed to recognize control targets. Further
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Bnalysis of donor 6, who was homozygous for the
LA-B35 allele, found that cultures stimulated with
ither CMV lysate or Ad5pp65GFP recognized the
LA-B35–restricted peptide VFP in cytotoxicity as-
ays; therefore, alternative epitopes are capable of
HC presentation in non–HLA-A2 culture systems.
The use of HLA-restricted peptides or tetramers to
elect CMV-speciﬁc T cells limits the number of eligible
atients who can receive CMV-speciﬁc immunotherapy.
lthough new epitopes from a variety of CMV proteins
re continually being discovered, methods to select
igure 7. Production of IFN- by sorted CD4 CMV-speciﬁc T
ells. CD4CMV-speciﬁc T cells from donor 1 were sorted by ﬂow
ytometry and plated in microtiter plates in triplicate. DCs either
oaded with CMV lysate transduced with Ad5pp65GFP or mock-
oaded were then used to stimulate the T cells. IFN- production in
esponse to stimulation was then measured by enzyme-linked im-
unosorbent assay. Both CMV lysate–stimulated and
d5pp65GFP-stimulated T-cell cultures contained CD4 T cells
apable of recognizing CMV antigens.
able 3. Phenotype and Expansion of HLA-A2 T-Cell Cultures
Antigen
Mean
CD4 CD8
d5pp65GFP 57  23 35  21
MV lysate 62  12 26  12Gated on lymphocytes as deﬁned by forward- and side-scatter proﬁle.
B&MTMV-speciﬁc T cells without knowledge of T-cell
pitope recognition would be useful. Our data demon-
trate 2 methods for the generation of broad immune
sion (%)* -Fold
Expansion
(Total)CD19 CD56
<1 10  10 10  5
<1 8  7 15  7
igure 8. Speciﬁcity of HLA-A2 CMV-speciﬁc T cells generated
rom Ad5pp65GFP-loaded and CMV lysate–loaded DCs. T-cell
ultures from an HLA-A2 donor (donor 7) were assayed for CMV
peciﬁcity by cytotoxicity and IFN- production by comparing the
esponse to stimulation by DCs loaded with Ad5pp65GFP, CMV
ysate, or control DCs. (A) Ad5pp65GFP-generated CMV-speciﬁc
cells lyse DC target cells transduced with Ad5pp65GFP (‘) and
MV lysate–pulsed DCs () but do not recognize Ad5GFP (□) or
ock-pulsed DC () target cells. (B) CMV lysate–generated CMV-
peciﬁc T cells lyse both DC target cells transduced with
d5pp65GFP (‘) and CMV lysate–pulsed DCs () but do not kill
d5GFP (□) or mock-pulsed DC () target cells. (C) CMV-
peciﬁc T cells derived from an HLA-B35 donor (donor 6) after
timulation with Ad5pp65GFP, CMV lysate, or VFP (HLA-B35–
estricted pp65 peptide) were tested for cytotoxicity against autol-
gous chromium-labeled DC target cells pulsed with either VFP or
rrelevant control peptide at a ratio of 50:1 effector/target cells.Expres769
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7esponses against CMV by using alternative methods of
ntigen stimulation in both HLA-A2 and HLA-A2
onors. Both lead to the generation of CMV-speciﬁc
D4 and CD8 T-cell types. From a clinical point of
iew, the use of CMV lysate for antigen stimulation is
otentially complicated by concerns regarding the use of
ndeﬁned antigens (potentially containing live virus or
ther infectious contaminants). Despite these concerns,
CMV lysate consisting of human ﬁbroblasts infected
ith a laboratory strain of CMV has been used by a
umber of groups to stimulate CMV-speciﬁc lympho-
ytes that were subsequently infused to patients without
eported adverse effects [3,25]. Although lysate prepara-
ions can be screened for live CMV by culture and
mmunoﬂuorescence and for other contaminants such as
epatitis and human immunodeﬁciency viruses by poly-
erase chain reaction, individual regulatory authorities
ill need to make decisions on the suitability of such
reparations for clinical use. The alternative approach
ith Ad5pp65GFP for stimulation of CMV-speciﬁc
ymphocytes requires clinical grade vector production
ut seems subject to less risk of contamination with viral
athogens or other adventitious agents.
In summary, CMV antigen preparations that in-
lude epitopes for a variety of HLA alleles, as well as
HC class II peptides, may facilitate the generation
f CD4 and CD8 CMV-speciﬁc lymphocytes in
oth HLA-A2 and HLA-A2 individuals. The in-
lusion of CD4 T cells in the lymphocyte population
ay enhance the efﬁcacy of CMV-speciﬁc T-cell
ransfer and allow for in vivo expansion and persis-
ence, although this effect has not yet been demon-
trated in clinical trials with CMV.
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